Kellerhals Carrard advises BVF Partners on its deal with NLS Pharmaceutics

As we have informed here NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announced that it has entered into a definitive agreement with funds managed by BVF Partners, a US fund manager, to raise aggregate gross proceeds of up to USD 30 million in a two-tranche private placement.

Kellerhals Carrard advised BVF on all Swiss legal aspects. The team consisted of partner Nicolas Mosimann (pictured), partner Marc Hanslin and Kevin MacCabe (all m&a/capital markets).